Skip to main content
. 2017 Sep 15;8(60):102531–102539. doi: 10.18632/oncotarget.20934

Figure 3.

Figure 3

(A) OS after recurrence of patients who underwent salvage treatment stratified by risks for early recurrence. (B) OS after recurrence in patients who underwent palliative chemotherapy stratified by risks for early recurrence.